ASP Isotopes (NASDAQ:ASPI) Shares Down 5.1% After Insider Selling

ASP Isotopes Inc. (NASDAQ:ASPI) shares dropped 5.1% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $4.79 and last traded at $4.8040. Approximately 2,717,844 shares traded hands during trading, a decline of 48% from the average daily volume of 5,234,062 shares. The stock had previously closed at $5.06.

Specifically, COO Robert Ainscow sold 25,000 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $4.51, for a total transaction of $112,750.00. Following the transaction, the chief operating officer directly owned 1,512,817 shares in the company, valued at $6,822,804.67. The trade was a 1.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Wall Street Analysts Forecast Growth

ASPI has been the topic of several research reports. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.00.

ASP Isotopes Stock Down 1.2%

The firm has a market capitalization of $629.50 million, a price-to-earnings ratio of -2.34 and a beta of 3.59. The company has a current ratio of 6.14, a quick ratio of 6.10 and a debt-to-equity ratio of 1.04. The firm has a fifty day moving average price of $5.08 and a 200 day moving average price of $6.79.

ASP Isotopes (NASDAQ:ASPI) last announced its earnings results on Friday, April 10th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.70). The business had revenue of $33.32 million during the quarter, compared to analyst estimates of $2.03 million. ASP Isotopes had a negative return on equity of 307.82% and a negative net margin of 734.14%. Sell-side analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ASPI. Quantbot Technologies LP acquired a new position in shares of ASP Isotopes in the 3rd quarter worth approximately $34,000. BNP Paribas Financial Markets boosted its holdings in shares of ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after acquiring an additional 2,548 shares in the last quarter. IFP Advisors Inc acquired a new position in shares of ASP Isotopes in the 4th quarter worth approximately $48,000. Pictet Asset Management Holding SA acquired a new position in shares of ASP Isotopes in the 4th quarter worth approximately $61,000. Finally, Close Asset Management Ltd acquired a new position in shares of ASP Isotopes in the 3rd quarter worth approximately $72,000. 16.80% of the stock is owned by institutional investors and hedge funds.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.